Erectaid uses negative pressure to distend the corporal sinusoids and to increase blood inflow to the penis. In this setting, an external constricting ring is placed at the base of the penis to prevent blood outflow from the corpora cavernosa, and an erection is maintained for sexual intercourse. As a non-invasive, effective, safe, drug-free and cost-effective erectile dysfunction (ED) treatment, VCD was gradually accepted by the urological community and was finally recommended as an alternative for treatment of ED by the American Urological Association in 1996.
Usage begins with placing the correct constriction ring over the open end of the vacuum cylinder. A copious amount of a water-soluble lubricant is then applied to the base of the penis to create a tight seal once the vacuum cylinder is placed over. Negative pressure generated by hand pump is then applied to create an artificial erection.Once the desired state of erection is achieved, the constriction ring is displaced onto the base of the penis to maintain the erect state. Variable constriction rings are available to select for those that are most comfortable and effective. The vacuum cylinders could then be removed and the patient may have intimacy. Patients can become proficient with the device within 5 days or four practice sessions. The time required to achieve an adequate penile erection ranges from 30 s to 7 minutes.
How to use - Erectaid Vacuum Constriction Device
Erectaid can be applied successfully for nearly all etiologies of ED; although its success depends on appropriate instruction and practice. More than 90% of men will experience functional erection with VCD therapy with adequate practice.
It is currently a second-line therapy along with intracavernosal self-injection and intraurethral therapy with vasoactive substances. It is widely believed that VCD therapy is more acceptable among elderly patients with occasional sexual intimacy, as younger patients may show limited acceptance because of its perceived ‘unnatural’ erection. Chen et al., conversely, reported that VCD therapy remained the preferred treatment option among couples who had achieved satisfactory erections with either VCDs and PDE5I.
Erectaid may also be used in conjunction with other therapies for synergistic effects. It has been reported that VCD therapy could be combined with PDE5I,intracavernosal self-injection, intraurethral therapy, psychotherapy and even penile prosthesis.
Contraindications to the use of Erectaid are few and primarily include patients with a tendency for spontaneous priapism or intermittent prolonged erections, and those with severe penile anomalies (either congenital or acquired). There are some relative contraindications, which can be overcome by education and precautious care, such as cultural taboo, cervical or high-thoracic spinal cord injuries, neurological disease or degenerative joint diseases with poor manual dexterity. Patients with bleeding disorders or those on anticoagulation therapy are considered at high risk to develop petechiae, eechymosis or hematoma; however, it was shown that the risk did not exceed that of the general population.